Qian Wang

The paper develops a monoclonal antibody panel to track antigenic evolution of SARS-CoV-2 JN.1 subvariants and identifies differences in antibody-evasion profiles between JN.1 and BA.3.2 lineages.

The paper identifies distinct CD8+ T-cell types associated with mild versus severe COVID-19 in unvaccinated HLA-A2+ patients, showing protective immunity correlates with specific cell subsets.

This study compares antibody evasion and receptor binding of SARS-CoV-2 subvariants, finding that LP.8.1.1 has high ACE2 affinity, while NB.1.8.1 and XFG show greater antibody evasion.

This study optimizes a human monoclonal antibody to enhance its neutralization of SARS-CoV-2 variants, including subvariants XEC and LP.8.1, through structural analysis and engineering.

This study assesses whether 2025 COVID-19 vaccines need updating by testing neutralizing antibody titers against emerging variants in individuals vaccinated with KP.2-based mRNA vaccines.

This study evaluates the antibody evasion of SARS-CoV-2 subvariants KP.3.1.1 and XEC compared to their parental variants, finding increased resistance to neutralization by sera and antibodies targeting the spike protein.

This study evaluates KP.2-based monovalent mRNA vaccines and finds they robustly boost neutralizing antibodies against current SARS-CoV-2 variants, including KP.3.1.1 and XEC.

This study develops a monoclonal antibody that broadly neutralizes multiple SARS-CoV-2 variants, including JN.1, and shows its protective efficacy in mice.

This study examines how recurrent spike mutations in SARS-CoV-2 JN.1 sublineages affect immune evasion, ACE2 affinity, and infectivity, identifying growth advantages in specific sublineages.

This study shows that neutralizing antibodies against SARS-CoV-2 variants remain stable for three months after an XBB.1.5 mRNA vaccine booster.

This study evaluates pemivibart's neutralizing activity against recent SARS-CoV-2 JN.1 sublineages and finds it has substantially reduced potency against KP.3.1.1.

This study compares the antibody evasion, ACE2 binding, and infectivity of SARS-CoV-2 BA.2.87.1 with EG.5.1 and JN.1, finding BA.2.87.1 has lower immune evasion and reduced infectivity.

The paper analyzes antibody neutralization data from multiple countries to assess how prior exposure to SARS-CoV-2 variants affects neutralization profiles of BA.2.86 and its descendants.

XBB.1.5 monovalent mRNA vaccine booster significantly increases neutralizing antibodies against multiple SARS-CoV-2 variants in both uninfected and previously infected individuals.

This paper evaluates the antigenicity and receptor affinity of the SARS-CoV-2 BA.2.86 subvariant, finding it not more resistant to human sera than other variants but with specific mAb resistance and high receptor affinity.

The paper shows that expressing broadly or poorly neutralizing antibodies or CD4 in HIV-1-producing cells reduces viral infectivity by disrupting Env processing and incorporation into virions.

The paper describes the engineering of HIV-1 Env variants enriched in a pretriggered conformation, which are more stable and crosslinkable, aiding in structural and immunogenic studies.

The paper predicts anti-HIV compounds and identifies novel human targets for anti-HIV therapy using a prediction tool and enrichment analysis.

The paper develops a web server to predict anti-HIV activity of compounds and identifies 7 approved drugs repurposed as anti-HIV agents.